Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Agrin as a prognostic biomarker in hepatocellular carcinoma.
Authors
Ankita Kapoor
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Ankita Kapoor , Sahithi Sonti , Riya Jayesh Patel , Anthony George , Kristopher Attwood , Kannan Thanikachalam , Renuka V. Iyer , Sayan Chakraborty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 559)
DOI
10.1200/JCO.2024.42.3_suppl.559
Abstract #
559
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma at early to intermediate stages (BCLC 0 to B).
First Author: Alexandre Prieur
Poster
2021 ASCO Annual Meeting
Prognostic value of plasma hPG80 (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.
First Author: Alexandre Prieur
Poster
2018 Gastrointestinal Cancers Symposium
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
First Author: Andrew X. Zhu
Poster
2023 ASCO Annual Meeting
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.
First Author: Rui Liu